Schering Says Smaller Is Better: Flexibility Aids Turnaround Process
Schering-Plough's smaller size will be an advantage as the company implements its turnaround plan, CEO Fred Hassan told investors during a business briefing in New York Nov. 18
You may also be interested in...
Schering-Plough's efficacy-based sales and marketing messages have helped stabilize share losses within the company's primary care business, Global Pharmaceutical President Carrie Cox said
Bayer is comfortable being a mid-sized European pharmaceutical company
Merck is on a pace to sign 50 outside R&D alliances during 2003